Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Streptococcus pneumoniae | 92 | 2021 | 714 | 13.530 |
Why?
|
Pneumococcal Infections | 73 | 2020 | 497 | 11.570 |
Why?
|
Influenza, Human | 70 | 2022 | 1479 | 9.590 |
Why?
|
Vaccines | 29 | 2024 | 823 | 8.160 |
Why?
|
Disease Outbreaks | 61 | 2024 | 1771 | 7.580 |
Why?
|
Pneumococcal Vaccines | 47 | 2020 | 391 | 6.170 |
Why?
|
Carrier State | 37 | 2019 | 518 | 4.890 |
Why?
|
Communicable Diseases | 21 | 2024 | 880 | 4.690 |
Why?
|
Anti-Bacterial Agents | 62 | 2022 | 7182 | 4.330 |
Why?
|
Pandemics | 54 | 2023 | 8385 | 4.300 |
Why?
|
Drug Resistance, Bacterial | 31 | 2022 | 1035 | 4.250 |
Why?
|
Influenza A Virus, H1N1 Subtype | 23 | 2016 | 459 | 4.030 |
Why?
|
Communicable Diseases, Emerging | 9 | 2023 | 157 | 3.540 |
Why?
|
Drug Resistance, Microbial | 25 | 2022 | 862 | 3.300 |
Why?
|
Pneumonia, Viral | 22 | 2020 | 3242 | 3.130 |
Why?
|
Coronavirus Infections | 21 | 2020 | 3135 | 3.100 |
Why?
|
Nasopharynx | 31 | 2018 | 379 | 2.980 |
Why?
|
Influenza A virus | 12 | 2018 | 456 | 2.920 |
Why?
|
Epidemics | 15 | 2022 | 523 | 2.710 |
Why?
|
Influenza Vaccines | 15 | 2020 | 738 | 2.500 |
Why?
|
Neisseria gonorrhoeae | 10 | 2020 | 238 | 2.470 |
Why?
|
Vaccination | 34 | 2023 | 3279 | 2.370 |
Why?
|
Disease Transmission, Infectious | 15 | 2020 | 547 | 2.340 |
Why?
|
Models, Biological | 41 | 2021 | 9584 | 2.280 |
Why?
|
Serotyping | 28 | 2018 | 338 | 2.080 |
Why?
|
Gonorrhea | 9 | 2020 | 335 | 2.070 |
Why?
|
Seasons | 18 | 2022 | 1493 | 2.040 |
Why?
|
Vaccines, Conjugate | 16 | 2020 | 333 | 2.000 |
Why?
|
Antigens, Bacterial | 13 | 2017 | 1172 | 2.000 |
Why?
|
Bacterial Infections | 17 | 2019 | 1401 | 1.980 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2024 | 9955 | 1.950 |
Why?
|
Research Design | 16 | 2021 | 5984 | 1.950 |
Why?
|
Bacteria | 19 | 2022 | 2115 | 1.930 |
Why?
|
Antigenic Variation | 6 | 2019 | 125 | 1.880 |
Why?
|
Bacterial Capsules | 11 | 2015 | 251 | 1.870 |
Why?
|
Viral Vaccines | 5 | 2020 | 636 | 1.850 |
Why?
|
Models, Statistical | 24 | 2021 | 5101 | 1.830 |
Why?
|
Communicable Disease Control | 13 | 2022 | 856 | 1.800 |
Why?
|
Models, Theoretical | 34 | 2024 | 3589 | 1.800 |
Why?
|
Coronavirus | 5 | 2020 | 158 | 1.660 |
Why?
|
Bacterial Vaccines | 9 | 2018 | 403 | 1.610 |
Why?
|
Oseltamivir | 5 | 2016 | 75 | 1.510 |
Why?
|
Immunity, Herd | 7 | 2021 | 44 | 1.490 |
Why?
|
Influenza A Virus, H5N1 Subtype | 8 | 2019 | 113 | 1.490 |
Why?
|
Drug Resistance, Multiple, Bacterial | 9 | 2019 | 567 | 1.450 |
Why?
|
Antibodies, Bacterial | 16 | 2018 | 1470 | 1.440 |
Why?
|
Respiratory Syncytial Virus Infections | 4 | 2019 | 329 | 1.430 |
Why?
|
Humans | 356 | 2024 | 744366 | 1.370 |
Why?
|
Computer Simulation | 26 | 2021 | 6194 | 1.350 |
Why?
|
Ethics, Research | 5 | 2019 | 191 | 1.350 |
Why?
|
Clinical Trials as Topic | 9 | 2021 | 7914 | 1.320 |
Why?
|
Population Surveillance | 14 | 2021 | 2616 | 1.290 |
Why?
|
Seroepidemiologic Studies | 7 | 2021 | 402 | 1.260 |
Why?
|
Biomedical Research | 10 | 2020 | 3309 | 1.260 |
Why?
|
Virus Diseases | 5 | 2019 | 711 | 1.260 |
Why?
|
Cross Infection | 9 | 2019 | 1417 | 1.240 |
Why?
|
Disease Susceptibility | 12 | 2024 | 1782 | 1.230 |
Why?
|
Immune Evasion | 5 | 2021 | 360 | 1.230 |
Why?
|
Staphylococcal Infections | 12 | 2020 | 1400 | 1.220 |
Why?
|
Containment of Biohazards | 5 | 2018 | 37 | 1.210 |
Why?
|
Genome, Bacterial | 11 | 2020 | 760 | 1.210 |
Why?
|
Azithromycin | 4 | 2022 | 196 | 1.140 |
Why?
|
Penicillin Resistance | 8 | 2020 | 84 | 1.120 |
Why?
|
Selection, Genetic | 15 | 2021 | 914 | 1.120 |
Why?
|
Mass Vaccination | 5 | 2021 | 105 | 1.100 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 6 | 2016 | 687 | 1.100 |
Why?
|
Epidemiologic Studies | 3 | 2020 | 676 | 1.090 |
Why?
|
Antiviral Agents | 12 | 2016 | 2987 | 1.060 |
Why?
|
Sexual Partners | 5 | 2019 | 729 | 1.030 |
Why?
|
Penicillins | 7 | 2022 | 380 | 1.010 |
Why?
|
Influenza in Birds | 4 | 2013 | 75 | 1.000 |
Why?
|
Travel | 7 | 2021 | 788 | 0.990 |
Why?
|
Ciprofloxacin | 3 | 2017 | 315 | 0.980 |
Why?
|
Epidemiologic Research Design | 2 | 2018 | 367 | 0.950 |
Why?
|
Ethics, Medical | 2 | 2022 | 792 | 0.950 |
Why?
|
Macrolides | 5 | 2022 | 201 | 0.950 |
Why?
|
Staphylococcus aureus | 11 | 2020 | 1453 | 0.920 |
Why?
|
Transformation, Bacterial | 5 | 2014 | 78 | 0.910 |
Why?
|
Epidemiologic Methods | 7 | 2020 | 1364 | 0.910 |
Why?
|
Sepsis | 5 | 2020 | 2593 | 0.910 |
Why?
|
Models, Immunological | 5 | 2019 | 527 | 0.900 |
Why?
|
Immunity, Cellular | 3 | 2019 | 1607 | 0.870 |
Why?
|
Haemophilus influenzae | 5 | 2016 | 172 | 0.860 |
Why?
|
Host-Pathogen Interactions | 8 | 2018 | 1480 | 0.860 |
Why?
|
Antibiosis | 4 | 2009 | 45 | 0.850 |
Why?
|
Whooping Cough | 3 | 2019 | 82 | 0.840 |
Why?
|
Antibodies, Viral | 5 | 2021 | 3177 | 0.840 |
Why?
|
Schools | 5 | 2021 | 1433 | 0.830 |
Why?
|
Ebola Vaccines | 3 | 2018 | 24 | 0.830 |
Why?
|
Pneumonia, Pneumococcal | 6 | 2011 | 127 | 0.830 |
Why?
|
Dose-Response Relationship, Immunologic | 2 | 2019 | 370 | 0.820 |
Why?
|
Immunization Programs | 7 | 2021 | 260 | 0.820 |
Why?
|
Public Health | 12 | 2023 | 2602 | 0.810 |
Why?
|
Drug Resistance, Viral | 7 | 2016 | 820 | 0.800 |
Why?
|
Sentinel Surveillance | 6 | 2020 | 281 | 0.800 |
Why?
|
Humidity | 3 | 2013 | 197 | 0.800 |
Why?
|
Escherichia coli Infections | 5 | 2020 | 532 | 0.790 |
Why?
|
Hemorrhagic Fever, Ebola | 5 | 2018 | 428 | 0.780 |
Why?
|
Coronaviridae Infections | 1 | 2020 | 10 | 0.770 |
Why?
|
Drug Prescriptions | 4 | 2022 | 1637 | 0.770 |
Why?
|
Hospitalization | 11 | 2022 | 10259 | 0.750 |
Why?
|
Adaptive Immunity | 4 | 2020 | 714 | 0.750 |
Why?
|
Orthomyxoviridae Infections | 2 | 2013 | 248 | 0.730 |
Why?
|
Prevalence | 32 | 2022 | 15221 | 0.730 |
Why?
|
Microbial Sensitivity Tests | 18 | 2020 | 1877 | 0.710 |
Why?
|
Disaster Planning | 4 | 2019 | 549 | 0.710 |
Why?
|
Severe Acute Respiratory Syndrome | 3 | 2007 | 137 | 0.710 |
Why?
|
Genetic Variation | 11 | 2019 | 6542 | 0.690 |
Why?
|
Therapeutic Human Experimentation | 1 | 2019 | 43 | 0.690 |
Why?
|
Off-Label Use | 1 | 2021 | 169 | 0.690 |
Why?
|
Incidence | 36 | 2023 | 20952 | 0.680 |
Why?
|
Post-Exposure Prophylaxis | 2 | 2024 | 102 | 0.680 |
Why?
|
Pneumonia, Bacterial | 2 | 2013 | 316 | 0.680 |
Why?
|
Cephalosporins | 3 | 2016 | 204 | 0.680 |
Why?
|
Meningitis, Meningococcal | 1 | 2019 | 43 | 0.680 |
Why?
|
Data Interpretation, Statistical | 6 | 2020 | 2716 | 0.670 |
Why?
|
Chemoprevention | 3 | 2019 | 319 | 0.670 |
Why?
|
Meningococcal Vaccines | 5 | 2019 | 95 | 0.670 |
Why?
|
Child, Preschool | 55 | 2022 | 41005 | 0.670 |
Why?
|
Hospital Bed Capacity | 1 | 2020 | 215 | 0.670 |
Why?
|
United States | 50 | 2023 | 69872 | 0.670 |
Why?
|
Sexual Behavior | 3 | 2019 | 2055 | 0.660 |
Why?
|
Basic Reproduction Number | 5 | 2020 | 31 | 0.660 |
Why?
|
Risk Assessment | 17 | 2022 | 23336 | 0.640 |
Why?
|
Escherichia coli | 9 | 2022 | 4217 | 0.640 |
Why?
|
Anti-Infective Agents | 2 | 2018 | 974 | 0.640 |
Why?
|
Asymptomatic Infections | 1 | 2019 | 128 | 0.630 |
Why?
|
Genetic Engineering | 2 | 2015 | 951 | 0.630 |
Why?
|
Haemophilus Infections | 3 | 2012 | 95 | 0.620 |
Why?
|
Metagenomics | 4 | 2020 | 428 | 0.620 |
Why?
|
Models, Genetic | 10 | 2017 | 3493 | 0.610 |
Why?
|
Science | 1 | 2020 | 241 | 0.600 |
Why?
|
Toxins, Biological | 1 | 2017 | 66 | 0.600 |
Why?
|
Biometry | 1 | 2020 | 558 | 0.600 |
Why?
|
Family Characteristics | 6 | 2022 | 1000 | 0.590 |
Why?
|
Infant | 46 | 2022 | 35134 | 0.590 |
Why?
|
Child | 63 | 2022 | 77709 | 0.590 |
Why?
|
Orthomyxoviridae | 5 | 2014 | 156 | 0.580 |
Why?
|
Bacterial Proteins | 11 | 2018 | 3854 | 0.580 |
Why?
|
Flavivirus | 1 | 2016 | 20 | 0.570 |
Why?
|
China | 7 | 2021 | 2245 | 0.570 |
Why?
|
Health Plan Implementation | 1 | 2020 | 352 | 0.570 |
Why?
|
Yellow Fever Vaccine | 1 | 2016 | 37 | 0.570 |
Why?
|
Research | 4 | 2018 | 1999 | 0.570 |
Why?
|
Population Dynamics | 9 | 2018 | 302 | 0.560 |
Why?
|
Yellow Fever | 1 | 2016 | 53 | 0.560 |
Why?
|
Drugs, Investigational | 1 | 2018 | 214 | 0.550 |
Why?
|
Chikungunya virus | 1 | 2016 | 50 | 0.550 |
Why?
|
Biological Evolution | 10 | 2021 | 1077 | 0.540 |
Why?
|
Ferrets | 2 | 2013 | 194 | 0.540 |
Why?
|
Statistics as Topic | 4 | 2019 | 2373 | 0.540 |
Why?
|
Infection Control | 6 | 2020 | 965 | 0.540 |
Why?
|
Age Factors | 14 | 2021 | 18373 | 0.540 |
Why?
|
Adolescent | 44 | 2022 | 85779 | 0.530 |
Why?
|
Recombination, Genetic | 5 | 2018 | 1586 | 0.530 |
Why?
|
Zoonoses | 1 | 2016 | 185 | 0.530 |
Why?
|
Health Care Rationing | 2 | 2012 | 437 | 0.530 |
Why?
|
Penicillin-Binding Proteins | 3 | 2014 | 137 | 0.520 |
Why?
|
Young Adult | 35 | 2021 | 56429 | 0.520 |
Why?
|
Cities | 4 | 2021 | 513 | 0.510 |
Why?
|
Virulence | 8 | 2018 | 1333 | 0.510 |
Why?
|
Respiration Disorders | 1 | 2018 | 371 | 0.510 |
Why?
|
Genetics, Population | 5 | 2018 | 934 | 0.490 |
Why?
|
Meningococcal Infections | 1 | 2014 | 77 | 0.490 |
Why?
|
Cefixime | 1 | 2014 | 12 | 0.490 |
Why?
|
Fluoroquinolones | 1 | 2016 | 310 | 0.490 |
Why?
|
Awareness | 1 | 2019 | 640 | 0.490 |
Why?
|
Immunity, Humoral | 1 | 2019 | 598 | 0.480 |
Why?
|
Cephalosporin Resistance | 1 | 2014 | 17 | 0.480 |
Why?
|
Databases, Protein | 1 | 2016 | 383 | 0.480 |
Why?
|
Bronchopneumonia | 1 | 2013 | 11 | 0.470 |
Why?
|
Interprofessional Relations | 1 | 2020 | 1011 | 0.470 |
Why?
|
Polymorphism, Genetic | 3 | 2021 | 4328 | 0.470 |
Why?
|
Health Status Disparities | 3 | 2021 | 1796 | 0.470 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2020 | 4386 | 0.460 |
Why?
|
Genomics | 7 | 2020 | 5717 | 0.460 |
Why?
|
Immunization | 4 | 2017 | 1256 | 0.460 |
Why?
|
Health Services Needs and Demand | 2 | 2020 | 1410 | 0.460 |
Why?
|
Sexually Transmitted Diseases | 1 | 2019 | 623 | 0.460 |
Why?
|
Parasitic Diseases | 4 | 1999 | 75 | 0.450 |
Why?
|
Israel | 11 | 2022 | 796 | 0.450 |
Why?
|
Immunization, Secondary | 5 | 2022 | 340 | 0.440 |
Why?
|
Static Electricity | 1 | 2013 | 263 | 0.440 |
Why?
|
Outpatients | 2 | 2020 | 1487 | 0.440 |
Why?
|
Safety | 2 | 2021 | 1186 | 0.430 |
Why?
|
Disasters | 1 | 2019 | 511 | 0.430 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1405 | 0.430 |
Why?
|
El Nino-Southern Oscillation | 1 | 2012 | 2 | 0.420 |
Why?
|
Adult | 55 | 2023 | 214052 | 0.410 |
Why?
|
Bacterial Typing Techniques | 3 | 2011 | 256 | 0.400 |
Why?
|
HIV Infections | 11 | 2022 | 16715 | 0.400 |
Why?
|
Ecology | 2 | 2019 | 106 | 0.400 |
Why?
|
Animals | 54 | 2021 | 168768 | 0.400 |
Why?
|
Computational Biology | 5 | 2020 | 3519 | 0.400 |
Why?
|
Bacterial Load | 4 | 2015 | 153 | 0.390 |
Why?
|
Virology | 2 | 2021 | 77 | 0.390 |
Why?
|
Antigens, Viral | 3 | 2013 | 1035 | 0.390 |
Why?
|
Streptococcal Infections | 1 | 2015 | 638 | 0.390 |
Why?
|
Forecasting | 6 | 2022 | 2951 | 0.380 |
Why?
|
Birds | 5 | 2019 | 163 | 0.380 |
Why?
|
Evolution, Molecular | 6 | 2018 | 1939 | 0.380 |
Why?
|
Antibody Formation | 4 | 2018 | 1402 | 0.380 |
Why?
|
Decision Making, Organizational | 1 | 2011 | 139 | 0.370 |
Why?
|
Publishing | 1 | 2018 | 833 | 0.370 |
Why?
|
Contact Tracing | 3 | 2021 | 273 | 0.370 |
Why?
|
Viruses | 3 | 2016 | 375 | 0.370 |
Why?
|
Phylogeny | 9 | 2022 | 2804 | 0.360 |
Why?
|
Child Day Care Centers | 4 | 2009 | 123 | 0.350 |
Why?
|
Viral Load | 5 | 2021 | 3300 | 0.350 |
Why?
|
Cholera | 2 | 2015 | 785 | 0.340 |
Why?
|
Time Factors | 24 | 2021 | 40075 | 0.340 |
Why?
|
Evidence-Based Medicine | 2 | 2020 | 3611 | 0.340 |
Why?
|
Cluster Analysis | 7 | 2020 | 2715 | 0.340 |
Why?
|
Otitis Media | 3 | 2018 | 277 | 0.330 |
Why?
|
Genotype | 10 | 2021 | 12952 | 0.330 |
Why?
|
Mathematics | 8 | 2004 | 728 | 0.330 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2021 | 2026 | 0.330 |
Why?
|
Molecular Biology | 1 | 2012 | 596 | 0.330 |
Why?
|
Age Distribution | 6 | 2020 | 2902 | 0.320 |
Why?
|
Alleles | 2 | 2014 | 6933 | 0.320 |
Why?
|
Ambulatory Care | 1 | 2019 | 2708 | 0.320 |
Why?
|
Civil Defense | 1 | 2010 | 109 | 0.320 |
Why?
|
Observation | 1 | 2010 | 312 | 0.320 |
Why?
|
Pertussis Vaccine | 2 | 2019 | 34 | 0.320 |
Why?
|
Genetic Fitness | 3 | 2015 | 121 | 0.320 |
Why?
|
Veterans | 1 | 2022 | 2519 | 0.310 |
Why?
|
Drug Resistance, Multiple | 4 | 1998 | 252 | 0.310 |
Why?
|
Molecular Epidemiology | 5 | 2017 | 468 | 0.310 |
Why?
|
California | 6 | 2022 | 1402 | 0.310 |
Why?
|
Female | 68 | 2022 | 380193 | 0.300 |
Why?
|
Bayes Theorem | 9 | 2021 | 2307 | 0.300 |
Why?
|
Public Health Practice | 3 | 2020 | 218 | 0.300 |
Why?
|
Quantitative Trait Loci | 2 | 2018 | 2019 | 0.300 |
Why?
|
beta-Lactamases | 3 | 2019 | 306 | 0.300 |
Why?
|
Critical Illness | 1 | 2020 | 2670 | 0.290 |
Why?
|
Probability | 6 | 2016 | 2506 | 0.290 |
Why?
|
Behavior | 1 | 2010 | 561 | 0.290 |
Why?
|
Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2019 | 157 | 0.290 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2012 | 546 | 0.290 |
Why?
|
Decision Support Techniques | 2 | 2018 | 1956 | 0.290 |
Why?
|
Sequence Analysis, DNA | 4 | 2020 | 4805 | 0.290 |
Why?
|
Placebos | 3 | 2021 | 1676 | 0.280 |
Why?
|
Weather | 2 | 2004 | 228 | 0.280 |
Why?
|
Proportional Hazards Models | 2 | 2019 | 12356 | 0.280 |
Why?
|
Neutrophils | 5 | 2013 | 3721 | 0.280 |
Why?
|
Singapore | 3 | 2020 | 295 | 0.280 |
Why?
|
Reproduction, Asexual | 1 | 2006 | 15 | 0.280 |
Why?
|
Tuberculosis | 5 | 2018 | 1912 | 0.280 |
Why?
|
Microbial Viability | 1 | 2007 | 234 | 0.280 |
Why?
|
Complement System Proteins | 1 | 2009 | 795 | 0.280 |
Why?
|
New York City | 4 | 2024 | 710 | 0.280 |
Why?
|
Hydrogen Peroxide | 2 | 2007 | 730 | 0.270 |
Why?
|
Th17 Cells | 1 | 2012 | 766 | 0.270 |
Why?
|
Health Policy | 7 | 2020 | 2661 | 0.270 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2015 | 3595 | 0.270 |
Why?
|
Male | 57 | 2022 | 350115 | 0.270 |
Why?
|
Species Specificity | 4 | 2018 | 2478 | 0.270 |
Why?
|
Indians, North American | 4 | 2011 | 355 | 0.270 |
Why?
|
Virus Shedding | 2 | 2020 | 108 | 0.270 |
Why?
|
Markov Chains | 2 | 2012 | 969 | 0.270 |
Why?
|
Herpesvirus 1, Human | 2 | 2002 | 743 | 0.270 |
Why?
|
Reference Books, Medical | 1 | 2005 | 22 | 0.260 |
Why?
|
Communication | 1 | 2019 | 3750 | 0.260 |
Why?
|
Community-Acquired Infections | 4 | 2011 | 465 | 0.260 |
Why?
|
Polysaccharides, Bacterial | 2 | 2006 | 578 | 0.260 |
Why?
|
Epistasis, Genetic | 3 | 2018 | 365 | 0.260 |
Why?
|
Complement Factor H | 2 | 2018 | 110 | 0.260 |
Why?
|
Peptidyl Transferases | 1 | 2005 | 54 | 0.260 |
Why?
|
AIDS Vaccines | 1 | 2012 | 938 | 0.260 |
Why?
|
Drug Utilization | 5 | 2019 | 1183 | 0.260 |
Why?
|
Middle Aged | 36 | 2022 | 213390 | 0.250 |
Why?
|
Streptococcal Vaccines | 1 | 2005 | 43 | 0.250 |
Why?
|
Genes, Bacterial | 4 | 2016 | 1079 | 0.250 |
Why?
|
Respiratory Tract Infections | 2 | 2022 | 961 | 0.250 |
Why?
|
Parasites | 3 | 1999 | 163 | 0.250 |
Why?
|
Measles | 3 | 2012 | 168 | 0.250 |
Why?
|
Colony Count, Microbial | 5 | 2012 | 331 | 0.250 |
Why?
|
South Africa | 5 | 2019 | 1731 | 0.240 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2016 | 10943 | 0.240 |
Why?
|
Quarantine | 3 | 2020 | 170 | 0.240 |
Why?
|
Population Density | 2 | 2023 | 196 | 0.240 |
Why?
|
Influenza A Virus, H3N2 Subtype | 2 | 2017 | 90 | 0.240 |
Why?
|
New York | 2 | 2021 | 886 | 0.240 |
Why?
|
Aged | 33 | 2022 | 163288 | 0.240 |
Why?
|
Databases, Factual | 2 | 2021 | 7730 | 0.230 |
Why?
|
Nose | 3 | 2020 | 509 | 0.230 |
Why?
|
Risk | 7 | 2022 | 9688 | 0.230 |
Why?
|
Kenya | 5 | 2012 | 685 | 0.220 |
Why?
|
Internet | 3 | 2018 | 3056 | 0.220 |
Why?
|
Health Surveys | 3 | 2014 | 4036 | 0.220 |
Why?
|
Niger | 2 | 2020 | 39 | 0.220 |
Why?
|
Animal Husbandry | 1 | 2003 | 66 | 0.220 |
Why?
|
beta-Lactam Resistance | 3 | 2016 | 79 | 0.210 |
Why?
|
Cost of Illness | 3 | 2021 | 1860 | 0.210 |
Why?
|
World Health Organization | 4 | 2021 | 1318 | 0.210 |
Why?
|
Genome, Human | 1 | 2015 | 4420 | 0.210 |
Why?
|
Fimbriae Proteins | 2 | 2014 | 134 | 0.210 |
Why?
|
Risk Management | 2 | 2016 | 571 | 0.210 |
Why?
|
Microbial Interactions | 2 | 2012 | 76 | 0.210 |
Why?
|
Cause of Death | 1 | 2012 | 3582 | 0.210 |
Why?
|
Nipah Virus | 1 | 2021 | 8 | 0.210 |
Why?
|
Immunoglobulin G | 6 | 2018 | 4561 | 0.200 |
Why?
|
Homosexuality, Male | 3 | 2019 | 1240 | 0.200 |
Why?
|
Mutagenesis | 1 | 2006 | 1264 | 0.200 |
Why?
|
Erythromycin | 3 | 2014 | 120 | 0.200 |
Why?
|
Aged, 80 and over | 14 | 2021 | 57776 | 0.200 |
Why?
|
Administrative Personnel | 1 | 2023 | 187 | 0.200 |
Why?
|
Coronaviridae | 1 | 2020 | 13 | 0.190 |
Why?
|
Mammals | 2 | 2020 | 1143 | 0.190 |
Why?
|
Haemophilus Vaccines | 2 | 1999 | 69 | 0.190 |
Why?
|
Mice | 20 | 2019 | 81201 | 0.190 |
Why?
|
Hong Kong | 3 | 2007 | 148 | 0.190 |
Why?
|
Herpes Labialis | 1 | 2000 | 29 | 0.190 |
Why?
|
Pharyngitis | 1 | 2022 | 215 | 0.190 |
Why?
|
Asthma | 1 | 2019 | 6010 | 0.190 |
Why?
|
Agriculture | 1 | 2002 | 186 | 0.190 |
Why?
|
Influenza B virus | 2 | 2011 | 50 | 0.190 |
Why?
|
Stochastic Processes | 4 | 2014 | 344 | 0.190 |
Why?
|
Coronavirus OC43, Human | 1 | 2020 | 18 | 0.190 |
Why?
|
Specimen Handling | 2 | 2020 | 694 | 0.190 |
Why?
|
Causality | 2 | 2022 | 1275 | 0.180 |
Why?
|
Risk Factors | 19 | 2021 | 72296 | 0.180 |
Why?
|
Wisconsin | 2 | 2010 | 124 | 0.180 |
Why?
|
Students | 1 | 2010 | 1647 | 0.180 |
Why?
|
Phagocytosis | 2 | 2018 | 1539 | 0.180 |
Why?
|
Multilocus Sequence Typing | 4 | 2015 | 100 | 0.180 |
Why?
|
Inappropriate Prescribing | 2 | 2022 | 202 | 0.180 |
Why?
|
Uncertainty | 2 | 2017 | 735 | 0.180 |
Why?
|
Vancomycin Resistance | 2 | 2014 | 128 | 0.180 |
Why?
|
Nasal Mucosa | 2 | 2015 | 373 | 0.180 |
Why?
|
History, 20th Century | 4 | 2009 | 2740 | 0.180 |
Why?
|
Social Welfare | 1 | 2020 | 87 | 0.170 |
Why?
|
Women, Working | 1 | 2020 | 87 | 0.170 |
Why?
|
Directed Molecular Evolution | 1 | 2020 | 160 | 0.170 |
Why?
|
Ducks | 1 | 2019 | 12 | 0.170 |
Why?
|
Neisseria meningitidis, Serogroup C | 1 | 2019 | 11 | 0.170 |
Why?
|
Mycobacterium tuberculosis | 3 | 2013 | 1832 | 0.170 |
Why?
|
Malaria, Falciparum | 2 | 2004 | 1077 | 0.170 |
Why?
|
Infant, Newborn | 15 | 2020 | 25628 | 0.170 |
Why?
|
Death Certificates | 1 | 2020 | 169 | 0.170 |
Why?
|
Rhinovirus | 1 | 2020 | 187 | 0.170 |
Why?
|
Immunity, Innate | 4 | 2012 | 2962 | 0.170 |
Why?
|
Mice, Inbred BALB C | 4 | 2013 | 6386 | 0.170 |
Why?
|
Herpes Simplex | 1 | 2002 | 470 | 0.170 |
Why?
|
Mutation | 13 | 2019 | 29786 | 0.170 |
Why?
|
Morals | 1 | 2021 | 285 | 0.160 |
Why?
|
Drug Utilization Review | 1 | 2020 | 245 | 0.160 |
Why?
|
Mice, Inbred C57BL | 12 | 2009 | 21833 | 0.160 |
Why?
|
Sample Size | 2 | 2019 | 845 | 0.160 |
Why?
|
Cross Reactions | 1 | 2020 | 841 | 0.160 |
Why?
|
Hospitals | 4 | 2022 | 3954 | 0.160 |
Why?
|
Health Services Administration | 1 | 2019 | 64 | 0.160 |
Why?
|
Europe | 6 | 2023 | 3338 | 0.160 |
Why?
|
Biohazard Release | 2 | 2021 | 9 | 0.160 |
Why?
|
Vaccines, Inactivated | 1 | 2018 | 184 | 0.160 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 738 | 0.160 |
Why?
|
Blood Bactericidal Activity | 1 | 2018 | 126 | 0.160 |
Why?
|
Epitopes | 2 | 2017 | 2571 | 0.160 |
Why?
|
Drug Resistance | 2 | 2006 | 1608 | 0.160 |
Why?
|
Adhesins, Bacterial | 2 | 2017 | 119 | 0.150 |
Why?
|
Mexico | 2 | 2010 | 689 | 0.150 |
Why?
|
Host-Parasite Interactions | 2 | 1997 | 295 | 0.150 |
Why?
|
Germany | 1 | 2020 | 862 | 0.150 |
Why?
|
Fimbriae, Bacterial | 2 | 2009 | 138 | 0.150 |
Why?
|
Health Priorities | 1 | 2021 | 380 | 0.150 |
Why?
|
Immunity | 4 | 2021 | 1014 | 0.150 |
Why?
|
Pyruvate Oxidase | 2 | 2007 | 7 | 0.150 |
Why?
|
Vitamin D | 1 | 2011 | 3224 | 0.150 |
Why?
|
Respiratory System | 2 | 2015 | 557 | 0.150 |
Why?
|
Heterosexuality | 3 | 2016 | 276 | 0.150 |
Why?
|
Angola | 1 | 2016 | 16 | 0.150 |
Why?
|
Insect Vectors | 2 | 2016 | 134 | 0.150 |
Why?
|
Beneficence | 1 | 2017 | 53 | 0.150 |
Why?
|
HLA Antigens | 1 | 2003 | 1382 | 0.150 |
Why?
|
England | 3 | 2018 | 522 | 0.150 |
Why?
|
Adaptation, Biological | 1 | 2018 | 153 | 0.150 |
Why?
|
Democratic Republic of the Congo | 1 | 2016 | 88 | 0.140 |
Why?
|
Linear Models | 3 | 2020 | 5953 | 0.140 |
Why?
|
Encephalitis Virus, Japanese | 1 | 2016 | 11 | 0.140 |
Why?
|
Yellow fever virus | 1 | 2016 | 22 | 0.140 |
Why?
|
Data Collection | 3 | 2011 | 3339 | 0.140 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 841 | 0.140 |
Why?
|
Survival Analysis | 4 | 2019 | 10252 | 0.140 |
Why?
|
Bioethics | 1 | 2018 | 116 | 0.140 |
Why?
|
Antitubercular Agents | 3 | 2011 | 1320 | 0.140 |
Why?
|
Microcephaly | 1 | 2020 | 432 | 0.140 |
Why?
|
Reproducibility of Results | 5 | 2022 | 19905 | 0.140 |
Why?
|
Algorithms | 6 | 2014 | 13882 | 0.140 |
Why?
|
Aging | 3 | 2012 | 8664 | 0.140 |
Why?
|
Sweden | 1 | 2019 | 1341 | 0.140 |
Why?
|
Severity of Illness Index | 5 | 2020 | 15535 | 0.140 |
Why?
|
West Nile virus | 1 | 2016 | 82 | 0.140 |
Why?
|
Neisseria meningitidis | 1 | 2016 | 109 | 0.140 |
Why?
|
Membrane Transport Proteins | 2 | 2017 | 1031 | 0.140 |
Why?
|
Catheter-Related Infections | 1 | 2019 | 252 | 0.140 |
Why?
|
RNA Virus Infections | 1 | 2015 | 17 | 0.130 |
Why?
|
Gene Flow | 1 | 2016 | 79 | 0.130 |
Why?
|
Peer Review | 1 | 2018 | 209 | 0.130 |
Why?
|
Insurance, Liability | 1 | 2016 | 102 | 0.130 |
Why?
|
Temperature | 4 | 2013 | 2204 | 0.130 |
Why?
|
Statistics, Nonparametric | 2 | 2013 | 2887 | 0.130 |
Why?
|
AIDS Serodiagnosis | 1 | 2016 | 184 | 0.130 |
Why?
|
Imipenem | 1 | 2014 | 38 | 0.130 |
Why?
|
Infant, Newborn, Diseases | 1 | 2020 | 582 | 0.130 |
Why?
|
Biological Science Disciplines | 1 | 2015 | 52 | 0.130 |
Why?
|
Enterobacter | 1 | 2014 | 46 | 0.130 |
Why?
|
Codon | 1 | 2017 | 611 | 0.130 |
Why?
|
Health Services Research | 2 | 2020 | 1836 | 0.130 |
Why?
|
Nasopharyngeal Diseases | 2 | 2012 | 25 | 0.130 |
Why?
|
Circumcision, Male | 1 | 2016 | 150 | 0.130 |
Why?
|
Ceftazidime | 1 | 2014 | 69 | 0.130 |
Why?
|
Human Experimentation | 1 | 2015 | 127 | 0.120 |
Why?
|
Moral Obligations | 1 | 2015 | 96 | 0.120 |
Why?
|
Capital Financing | 1 | 2014 | 58 | 0.120 |
Why?
|
Treatment Refusal | 1 | 1998 | 421 | 0.120 |
Why?
|
Expressed Sequence Tags | 1 | 2015 | 255 | 0.120 |
Why?
|
Spain | 2 | 2020 | 465 | 0.120 |
Why?
|
Dengue Virus | 1 | 2016 | 204 | 0.120 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2029 | 0.120 |
Why?
|
Child Mortality | 2 | 2020 | 198 | 0.120 |
Why?
|
Malaria | 1 | 2004 | 1239 | 0.120 |
Why?
|
Gene Order | 1 | 2014 | 176 | 0.120 |
Why?
|
Condoms | 1 | 2016 | 323 | 0.120 |
Why?
|
Ethiopia | 3 | 2004 | 495 | 0.120 |
Why?
|
Cytomegalovirus Infections | 1 | 2020 | 820 | 0.120 |
Why?
|
Massachusetts | 11 | 2019 | 8662 | 0.120 |
Why?
|
Regression Analysis | 3 | 2013 | 6459 | 0.120 |
Why?
|
Fungi | 1 | 1997 | 327 | 0.120 |
Why?
|
Genome, Viral | 2 | 2014 | 667 | 0.120 |
Why?
|
Genes, RAG-1 | 1 | 2013 | 68 | 0.120 |
Why?
|
Myocarditis | 1 | 2021 | 771 | 0.120 |
Why?
|
Immunologic Memory | 1 | 2020 | 1348 | 0.120 |
Why?
|
Tuberculosis, Multidrug-Resistant | 3 | 2013 | 912 | 0.120 |
Why?
|
Plasmids | 2 | 2014 | 2308 | 0.110 |
Why?
|
Treatment Outcome | 10 | 2022 | 63107 | 0.110 |
Why?
|
Mycoses | 1 | 1997 | 376 | 0.110 |
Why?
|
Minority Groups | 1 | 2021 | 1221 | 0.110 |
Why?
|
DNA, Bacterial | 5 | 2013 | 1465 | 0.110 |
Why?
|
Fever | 2 | 2011 | 1616 | 0.110 |
Why?
|
Intensive Care Units | 4 | 2020 | 3680 | 0.110 |
Why?
|
Shiga-Toxigenic Escherichia coli | 1 | 2013 | 28 | 0.110 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 2004 | 769 | 0.110 |
Why?
|
Vaccines, Subunit | 1 | 2013 | 168 | 0.110 |
Why?
|
Gene Frequency | 3 | 2013 | 3587 | 0.110 |
Why?
|
Complement C3b | 1 | 2012 | 106 | 0.110 |
Why?
|
Laboratory Infection | 1 | 2012 | 7 | 0.110 |
Why?
|
Virulence Factors | 1 | 2016 | 509 | 0.110 |
Why?
|
Interleukin-17 | 3 | 2008 | 901 | 0.110 |
Why?
|
Comorbidity | 3 | 2019 | 10388 | 0.110 |
Why?
|
Heat-Shock Proteins | 1 | 2017 | 822 | 0.110 |
Why?
|
Informed Consent | 1 | 2019 | 995 | 0.110 |
Why?
|
Urinary Tract Infections | 1 | 2019 | 788 | 0.110 |
Why?
|
Cholera Toxin | 2 | 2013 | 556 | 0.110 |
Why?
|
Pacific Ocean | 1 | 2012 | 16 | 0.110 |
Why?
|
Animal Migration | 1 | 2012 | 6 | 0.110 |
Why?
|
Zimbabwe | 1 | 2012 | 129 | 0.110 |
Why?
|
Retrospective Studies | 13 | 2022 | 77460 | 0.110 |
Why?
|
Feasibility Studies | 2 | 2021 | 5077 | 0.100 |
Why?
|
Water Purification | 1 | 2012 | 48 | 0.100 |
Why?
|
Pseudomonas aeruginosa | 2 | 2014 | 1219 | 0.100 |
Why?
|
Brazil | 1 | 2016 | 1270 | 0.100 |
Why?
|
Administration, Oral | 1 | 2020 | 3914 | 0.100 |
Why?
|
Security Measures | 1 | 2012 | 77 | 0.100 |
Why?
|
Endocarditis | 1 | 2016 | 349 | 0.100 |
Why?
|
Models, Economic | 1 | 2016 | 712 | 0.100 |
Why?
|
Enterococcus | 2 | 2004 | 157 | 0.100 |
Why?
|
Longitudinal Studies | 5 | 2018 | 13991 | 0.100 |
Why?
|
Anti-HIV Agents | 2 | 2019 | 4255 | 0.100 |
Why?
|
Administration, Intranasal | 4 | 2007 | 446 | 0.100 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2014 | 139 | 0.100 |
Why?
|
Canada | 2 | 2009 | 2065 | 0.100 |
Why?
|
Endocarditis, Bacterial | 1 | 2015 | 455 | 0.100 |
Why?
|
Germ Cells | 1 | 2015 | 631 | 0.100 |
Why?
|
Case-Control Studies | 6 | 2021 | 21748 | 0.100 |
Why?
|
Wales | 1 | 2011 | 85 | 0.100 |
Why?
|
Gram-Positive Bacterial Infections | 2 | 2004 | 341 | 0.100 |
Why?
|
Urban Population | 1 | 2019 | 2022 | 0.100 |
Why?
|
Thailand | 1 | 2012 | 296 | 0.100 |
Why?
|
Rotavirus Infections | 1 | 2012 | 86 | 0.100 |
Why?
|
Technology, Pharmaceutical | 1 | 2011 | 84 | 0.100 |
Why?
|
Residence Characteristics | 1 | 2021 | 2050 | 0.100 |
Why?
|
Commerce | 1 | 2016 | 592 | 0.100 |
Why?
|
Michigan | 1 | 2011 | 350 | 0.090 |
Why?
|
Complement C3 | 1 | 2012 | 461 | 0.090 |
Why?
|
Meningitis, Pneumococcal | 1 | 2010 | 42 | 0.090 |
Why?
|
Measles Vaccine | 1 | 2010 | 76 | 0.090 |
Why?
|
Microsatellite Repeats | 1 | 2013 | 802 | 0.090 |
Why?
|
Viral Proteins | 2 | 2016 | 1900 | 0.090 |
Why?
|
International Classification of Diseases | 3 | 2022 | 867 | 0.090 |
Why?
|
Haiti | 1 | 2012 | 553 | 0.090 |
Why?
|
Leukocyte Reduction Procedures | 1 | 2009 | 15 | 0.090 |
Why?
|
Antibiotic Prophylaxis | 1 | 2015 | 639 | 0.090 |
Why?
|
RNA | 1 | 2020 | 2749 | 0.090 |
Why?
|
Multigene Family | 1 | 2013 | 1102 | 0.090 |
Why?
|
Vapor Pressure | 1 | 2009 | 1 | 0.090 |
Why?
|
Denmark | 1 | 2012 | 738 | 0.090 |
Why?
|
Licensure | 2 | 2020 | 125 | 0.090 |
Why?
|
Odds Ratio | 3 | 2018 | 9849 | 0.090 |
Why?
|
Base Sequence | 4 | 2014 | 12797 | 0.090 |
Why?
|
Mortality | 3 | 2020 | 2864 | 0.090 |
Why?
|
Philadelphia | 1 | 2009 | 267 | 0.090 |
Why?
|
Health Care Costs | 2 | 2018 | 3208 | 0.090 |
Why?
|
Prospective Studies | 8 | 2018 | 53290 | 0.090 |
Why?
|
Disease Notification | 1 | 2009 | 97 | 0.080 |
Why?
|
Isoniazid | 2 | 2011 | 274 | 0.080 |
Why?
|
Logistic Models | 5 | 2017 | 13409 | 0.080 |
Why?
|
Attitude of Health Personnel | 1 | 2003 | 3841 | 0.080 |
Why?
|
Primary Prevention | 1 | 2016 | 1167 | 0.080 |
Why?
|
Models, Animal | 1 | 2015 | 2173 | 0.080 |
Why?
|
Proteome | 1 | 2018 | 1798 | 0.080 |
Why?
|
Immunocompromised Host | 1 | 2014 | 847 | 0.080 |
Why?
|
Absenteeism | 1 | 2010 | 250 | 0.080 |
Why?
|
Rural Population | 1 | 2019 | 2207 | 0.080 |
Why?
|
Colonoscopy | 1 | 2016 | 1367 | 0.080 |
Why?
|
Vibrio cholerae | 1 | 2015 | 807 | 0.080 |
Why?
|
Inpatients | 1 | 2020 | 2518 | 0.080 |
Why?
|
Helicobacter pylori | 1 | 2011 | 383 | 0.080 |
Why?
|
Food Microbiology | 1 | 2008 | 78 | 0.080 |
Why?
|
Helicobacter Infections | 1 | 2011 | 387 | 0.080 |
Why?
|
Family Health | 2 | 2010 | 1281 | 0.080 |
Why?
|
Cells, Cultured | 3 | 2013 | 19233 | 0.080 |
Why?
|
Latent Tuberculosis | 1 | 2011 | 225 | 0.080 |
Why?
|
Cohort Studies | 6 | 2022 | 40559 | 0.080 |
Why?
|
Occupational Health | 1 | 2014 | 808 | 0.080 |
Why?
|
Rain | 2 | 2004 | 61 | 0.080 |
Why?
|
Parents | 1 | 2022 | 3405 | 0.080 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 1995 | 1320 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 2 | 2007 | 17446 | 0.080 |
Why?
|
Decision Making | 3 | 2019 | 3888 | 0.080 |
Why?
|
Protein Binding | 2 | 2018 | 9384 | 0.080 |
Why?
|
Patient Compliance | 1 | 2018 | 2684 | 0.080 |
Why?
|
Health Personnel | 1 | 2021 | 3219 | 0.080 |
Why?
|
HIV | 1 | 1995 | 1604 | 0.080 |
Why?
|
Asymptomatic Diseases | 2 | 2021 | 551 | 0.080 |
Why?
|
Public Policy | 1 | 2012 | 572 | 0.080 |
Why?
|
Multivariate Analysis | 6 | 2012 | 12244 | 0.080 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2005 | 3873 | 0.080 |
Why?
|
Double-Blind Method | 2 | 2018 | 12025 | 0.080 |
Why?
|
Resource Allocation | 1 | 2009 | 341 | 0.080 |
Why?
|
Insurance, Health | 1 | 2020 | 2494 | 0.070 |
Why?
|
Cohort Effect | 1 | 2007 | 39 | 0.070 |
Why?
|
Fructose | 1 | 2009 | 289 | 0.070 |
Why?
|
Health Promotion | 1 | 2019 | 2205 | 0.070 |
Why?
|
Public Opinion | 1 | 2011 | 477 | 0.070 |
Why?
|
Sensitivity and Specificity | 3 | 2009 | 14723 | 0.070 |
Why?
|
Environmental Pollutants | 1 | 2016 | 1179 | 0.070 |
Why?
|
Geography | 2 | 2014 | 669 | 0.070 |
Why?
|
Respiratory Tract Diseases | 1 | 2012 | 722 | 0.070 |
Why?
|
Planning Techniques | 1 | 2007 | 82 | 0.070 |
Why?
|
Socioeconomic Factors | 2 | 2018 | 7785 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2460 | 0.070 |
Why?
|
Antibodies | 1 | 2015 | 2460 | 0.070 |
Why?
|
Poisson Distribution | 2 | 2004 | 513 | 0.070 |
Why?
|
Streptolysins | 2 | 2004 | 55 | 0.070 |
Why?
|
Occupational Diseases | 1 | 2014 | 1469 | 0.070 |
Why?
|
History, 21st Century | 1 | 2012 | 1534 | 0.070 |
Why?
|
Chromosome Mapping | 1 | 2014 | 4740 | 0.070 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2007 | 424 | 0.070 |
Why?
|
Mucous Membrane | 1 | 2009 | 673 | 0.070 |
Why?
|
Catalase | 1 | 2006 | 221 | 0.070 |
Why?
|
Phenotype | 4 | 2014 | 16367 | 0.070 |
Why?
|
Cost-Benefit Analysis | 1 | 2018 | 5388 | 0.070 |
Why?
|
Universities | 1 | 2011 | 951 | 0.070 |
Why?
|
DNA | 1 | 2020 | 7294 | 0.070 |
Why?
|
Intestines | 1 | 2015 | 1924 | 0.070 |
Why?
|
Ethics Committees | 1 | 2005 | 54 | 0.060 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2018 | 15520 | 0.060 |
Why?
|
Patient Acceptance of Health Care | 1 | 2018 | 3020 | 0.060 |
Why?
|
Ethicists | 1 | 2005 | 37 | 0.060 |
Why?
|
Evidence-Based Practice | 1 | 2009 | 501 | 0.060 |
Why?
|
Molecular Sequence Data | 4 | 2014 | 18111 | 0.060 |
Why?
|
Developing Countries | 1 | 2017 | 2815 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2017 | 39052 | 0.060 |
Why?
|
Ecosystem | 1 | 2008 | 474 | 0.060 |
Why?
|
Pneumonia | 2 | 2013 | 2133 | 0.060 |
Why?
|
Vietnam | 1 | 2004 | 408 | 0.060 |
Why?
|
Morbidity | 1 | 2009 | 1768 | 0.060 |
Why?
|
Patient Transfer | 1 | 2010 | 762 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5321 | 0.060 |
Why?
|
Area Under Curve | 2 | 2020 | 1655 | 0.060 |
Why?
|
Cell Wall | 1 | 2006 | 422 | 0.050 |
Why?
|
Patient Isolation | 1 | 2003 | 100 | 0.050 |
Why?
|
Bacterial Physiological Phenomena | 2 | 2000 | 121 | 0.050 |
Why?
|
Animals, Domestic | 1 | 2002 | 56 | 0.050 |
Why?
|
Campylobacter | 1 | 2002 | 59 | 0.050 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2006 | 657 | 0.050 |
Why?
|
Age of Onset | 1 | 2009 | 3270 | 0.050 |
Why?
|
Linkage Disequilibrium | 2 | 2018 | 1997 | 0.050 |
Why?
|
Treatment Failure | 2 | 2021 | 2618 | 0.050 |
Why?
|
Endemic Diseases | 1 | 2003 | 182 | 0.050 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2006 | 1369 | 0.050 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2004 | 232 | 0.050 |
Why?
|
Malawi | 1 | 2023 | 282 | 0.050 |
Why?
|
Sex Factors | 2 | 2013 | 10400 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2021 | 15160 | 0.050 |
Why?
|
Lactams | 1 | 2022 | 156 | 0.050 |
Why?
|
Anti-Retroviral Agents | 2 | 2012 | 1714 | 0.050 |
Why?
|
Medicare | 2 | 2018 | 6566 | 0.050 |
Why?
|
Herpes Genitalis | 1 | 2002 | 140 | 0.050 |
Why?
|
Gene Transfer, Horizontal | 1 | 2002 | 145 | 0.050 |
Why?
|
Carnobacteriaceae | 1 | 2020 | 10 | 0.050 |
Why?
|
Kidney Diseases | 1 | 2012 | 2148 | 0.050 |
Why?
|
Amoxicillin | 2 | 2018 | 170 | 0.050 |
Why?
|
Herpesvirus 2, Human | 1 | 2002 | 189 | 0.050 |
Why?
|
Amino Acid Substitution | 1 | 2006 | 1793 | 0.050 |
Why?
|
Cefotaxime | 1 | 2000 | 35 | 0.050 |
Why?
|
Disease Models, Animal | 5 | 2012 | 18034 | 0.050 |
Why?
|
Vancomycin | 1 | 2004 | 501 | 0.050 |
Why?
|
Leucine | 1 | 2022 | 560 | 0.050 |
Why?
|
Voluntary Programs | 1 | 2020 | 42 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2020 | 1254 | 0.050 |
Why?
|
Immunoglobulin A | 1 | 2004 | 995 | 0.050 |
Why?
|
Ritonavir | 1 | 2022 | 322 | 0.050 |
Why?
|
Proline | 1 | 2022 | 458 | 0.050 |
Why?
|
Streptococcus | 1 | 2020 | 197 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6539 | 0.050 |
Why?
|
Mice, Knockout | 2 | 2013 | 14561 | 0.050 |
Why?
|
Serologic Tests | 1 | 2002 | 374 | 0.050 |
Why?
|
Genes, Recessive | 1 | 2003 | 641 | 0.050 |
Why?
|
Aircraft | 1 | 2021 | 123 | 0.040 |
Why?
|
Gene Deletion | 1 | 2008 | 2751 | 0.040 |
Why?
|
Genes, Dominant | 1 | 2003 | 880 | 0.040 |
Why?
|
Emigration and Immigration | 1 | 2003 | 402 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2017 | 7882 | 0.040 |
Why?
|
Vaccines, Synthetic | 1 | 2022 | 634 | 0.040 |
Why?
|
Bangladesh | 1 | 2021 | 687 | 0.040 |
Why?
|
Acute Disease | 2 | 2021 | 7147 | 0.040 |
Why?
|
Ontario | 1 | 2020 | 383 | 0.040 |
Why?
|
Amino Acid Sequence | 2 | 2014 | 13814 | 0.040 |
Why?
|
Clavulanic Acid | 1 | 2018 | 19 | 0.040 |
Why?
|
Family | 1 | 2010 | 3147 | 0.040 |
Why?
|
Puerto Rico | 1 | 2020 | 356 | 0.040 |
Why?
|
Aluminum Hydroxide | 1 | 2018 | 58 | 0.040 |
Why?
|
Herpes Zoster | 1 | 2021 | 264 | 0.040 |
Why?
|
Luminescent Measurements | 1 | 2001 | 405 | 0.040 |
Why?
|
Africa | 1 | 2021 | 672 | 0.040 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2006 | 1821 | 0.040 |
Why?
|
Homozygote | 1 | 2003 | 1787 | 0.040 |
Why?
|
Social Isolation | 1 | 2020 | 365 | 0.040 |
Why?
|
Privacy | 1 | 2020 | 238 | 0.040 |
Why?
|
Cross-Sectional Studies | 5 | 2021 | 25039 | 0.040 |
Why?
|
Crossing Over, Genetic | 1 | 1997 | 95 | 0.040 |
Why?
|
Sierra Leone | 1 | 2017 | 166 | 0.040 |
Why?
|
DNA Transposable Elements | 1 | 2001 | 748 | 0.040 |
Why?
|
Metagenome | 1 | 2020 | 418 | 0.040 |
Why?
|
Insurance | 1 | 2018 | 111 | 0.040 |
Why?
|
Medicare Part C | 1 | 2022 | 296 | 0.040 |
Why?
|
Adjuvants, Immunologic | 2 | 2018 | 1000 | 0.040 |
Why?
|
Nitriles | 1 | 2022 | 955 | 0.040 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2020 | 954 | 0.040 |
Why?
|
Glucose | 1 | 2009 | 4398 | 0.040 |
Why?
|
Protein Array Analysis | 1 | 2018 | 411 | 0.040 |
Why?
|
Drug Combinations | 1 | 2022 | 1958 | 0.040 |
Why?
|
Critical Care | 1 | 2009 | 2647 | 0.040 |
Why?
|
Dengue | 1 | 2020 | 256 | 0.040 |
Why?
|
DNA, Fungal | 1 | 1997 | 280 | 0.030 |
Why?
|
Neonatal Screening | 1 | 2020 | 591 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 2020 | 733 | 0.030 |
Why?
|
Length of Stay | 1 | 2009 | 6311 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2015 | 6773 | 0.030 |
Why?
|
Arabs | 1 | 2017 | 178 | 0.030 |
Why?
|
Operon | 2 | 2010 | 363 | 0.030 |
Why?
|
Pregnancy | 3 | 2021 | 29144 | 0.030 |
Why?
|
Mice, Transgenic | 1 | 2008 | 9735 | 0.030 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2015 | 31 | 0.030 |
Why?
|
Drug Therapy, Combination | 3 | 2009 | 6489 | 0.030 |
Why?
|
Survival | 1 | 2015 | 163 | 0.030 |
Why?
|
HTLV-I Infections | 1 | 1995 | 101 | 0.030 |
Why?
|
Propensity Score | 1 | 2022 | 1781 | 0.030 |
Why?
|
Minnesota | 1 | 2015 | 344 | 0.030 |
Why?
|
Rats | 3 | 2007 | 24252 | 0.030 |
Why?
|
Appendicitis | 1 | 2021 | 645 | 0.030 |
Why?
|
Dogs | 1 | 2019 | 3912 | 0.030 |
Why?
|
Public Health Administration | 1 | 1997 | 240 | 0.030 |
Why?
|
Medical Record Linkage | 1 | 2015 | 284 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2016 | 15297 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2012 | 5749 | 0.030 |
Why?
|
Prognosis | 3 | 2021 | 29060 | 0.030 |
Why?
|
Disease Progression | 2 | 2017 | 13286 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2021 | 4751 | 0.030 |
Why?
|
Environmental Exposure | 1 | 2008 | 4232 | 0.030 |
Why?
|
Drosophila Proteins | 1 | 2003 | 1703 | 0.030 |
Why?
|
Genetic Speciation | 1 | 2013 | 46 | 0.030 |
Why?
|
Entropy | 1 | 2014 | 209 | 0.030 |
Why?
|
Research Personnel | 1 | 2018 | 573 | 0.030 |
Why?
|
Research Subjects | 1 | 2015 | 239 | 0.030 |
Why?
|
Receptors, Cell Surface | 1 | 2003 | 2865 | 0.030 |
Why?
|
Attitude | 1 | 2018 | 776 | 0.030 |
Why?
|
Genetic Markers | 1 | 2019 | 2634 | 0.030 |
Why?
|
Interspersed Repetitive Sequences | 1 | 2013 | 54 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2020 | 1783 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11126 | 0.030 |
Why?
|
Antibiotics, Antitubercular | 1 | 2013 | 104 | 0.030 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 3047 | 0.030 |
Why?
|
Animals, Newborn | 2 | 2009 | 2726 | 0.030 |
Why?
|
Ventilation | 1 | 2013 | 127 | 0.030 |
Why?
|
Biomarkers, Pharmacological | 1 | 2013 | 162 | 0.030 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2013 | 110 | 0.030 |
Why?
|
New Mexico | 1 | 2011 | 86 | 0.030 |
Why?
|
Arizona | 1 | 2011 | 108 | 0.030 |
Why?
|
Pregnancy Outcome | 1 | 2002 | 2795 | 0.030 |
Why?
|
Membrane Glycoproteins | 1 | 2003 | 3771 | 0.030 |
Why?
|
Calibration | 1 | 2014 | 816 | 0.020 |
Why?
|
Alzheimer Disease | 1 | 2012 | 8038 | 0.020 |
Why?
|
Clinical Protocols | 1 | 1997 | 1461 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2018 | 1312 | 0.020 |
Why?
|
Policy Making | 1 | 2015 | 554 | 0.020 |
Why?
|
Methicillin | 1 | 2011 | 59 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 2960 | 0.020 |
Why?
|
SEER Program | 1 | 2015 | 1507 | 0.020 |
Why?
|
Methicillin Resistance | 1 | 2011 | 198 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2019 | 1178 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2015 | 2256 | 0.020 |
Why?
|
Sex Distribution | 1 | 2015 | 2297 | 0.020 |
Why?
|
Demography | 1 | 1995 | 1655 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1872 | 0.020 |
Why?
|
Mothers | 1 | 2020 | 2165 | 0.020 |
Why?
|
United Nations | 1 | 2010 | 165 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2014 | 2839 | 0.020 |
Why?
|
Immunization Schedule | 1 | 2010 | 221 | 0.020 |
Why?
|
Netherlands | 1 | 2014 | 2170 | 0.020 |
Why?
|
Medical Audit | 1 | 2010 | 467 | 0.020 |
Why?
|
Neuraminidase | 1 | 2009 | 210 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 2011 | 915 | 0.020 |
Why?
|
International Cooperation | 1 | 2015 | 1420 | 0.020 |
Why?
|
Recurrence | 1 | 2000 | 8340 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4216 | 0.020 |
Why?
|
Carbon Dioxide | 1 | 2013 | 1150 | 0.020 |
Why?
|
Rabbits | 1 | 2015 | 4894 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2015 | 20824 | 0.020 |
Why?
|
HIV-1 | 1 | 2006 | 6939 | 0.020 |
Why?
|
Nasal Cavity | 1 | 2009 | 313 | 0.020 |
Why?
|
Chronic Disease | 1 | 2022 | 9145 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2022 | 13035 | 0.020 |
Why?
|
Saccharomyces cerevisiae | 1 | 1997 | 2751 | 0.020 |
Why?
|
Environmental Monitoring | 1 | 2013 | 1414 | 0.020 |
Why?
|
Idaho | 1 | 2005 | 16 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1995 | 2232 | 0.020 |
Why?
|
ROC Curve | 1 | 2014 | 3528 | 0.020 |
Why?
|
Australia | 1 | 2009 | 1167 | 0.020 |
Why?
|
Utah | 1 | 2005 | 126 | 0.020 |
Why?
|
Adoptive Transfer | 1 | 2008 | 844 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 2971 | 0.020 |
Why?
|
Diarrhea | 1 | 2013 | 1348 | 0.020 |
Why?
|
Software | 1 | 2020 | 4441 | 0.020 |
Why?
|
Lymphocyte Depletion | 1 | 2007 | 608 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2007 | 712 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2011 | 3508 | 0.020 |
Why?
|
Drug Industry | 1 | 2011 | 746 | 0.020 |
Why?
|
Nutrition Surveys | 1 | 2011 | 1660 | 0.020 |
Why?
|
Culicidae | 1 | 2004 | 105 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 15078 | 0.010 |
Why?
|
Immunoglobulins | 1 | 2007 | 881 | 0.010 |
Why?
|
Rats, Sprague-Dawley | 2 | 2007 | 8300 | 0.010 |
Why?
|
Africa South of the Sahara | 1 | 2006 | 724 | 0.010 |
Why?
|
Self Report | 1 | 2014 | 3553 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2022 | 7658 | 0.010 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2003 | 300 | 0.010 |
Why?
|
Protein Subunits | 1 | 2006 | 959 | 0.010 |
Why?
|
Lung | 1 | 2001 | 9857 | 0.010 |
Why?
|
Macrophages, Peritoneal | 1 | 2003 | 251 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 2003 | 964 | 0.010 |
Why?
|
Trachea | 1 | 2007 | 1076 | 0.010 |
Why?
|
Risk-Taking | 1 | 2007 | 986 | 0.010 |
Why?
|
Spleen | 1 | 2007 | 2362 | 0.010 |
Why?
|
Toll-Like Receptor 2 | 1 | 2003 | 354 | 0.010 |
Why?
|
Porins | 1 | 2000 | 81 | 0.010 |
Why?
|
Toll-Like Receptor 4 | 1 | 2003 | 565 | 0.010 |
Why?
|
Mice, Nude | 1 | 2006 | 3689 | 0.010 |
Why?
|
Toll-Like Receptors | 1 | 2003 | 593 | 0.010 |
Why?
|
Virus Physiological Phenomena | 1 | 1999 | 18 | 0.010 |
Why?
|
Chromosomes, Bacterial | 1 | 2000 | 282 | 0.010 |
Why?
|
Lipoproteins | 1 | 2004 | 878 | 0.010 |
Why?
|
Cricetinae | 1 | 2003 | 2475 | 0.010 |
Why?
|
Immunization, Passive | 1 | 2001 | 623 | 0.010 |
Why?
|
DNA Primers | 1 | 2003 | 2891 | 0.010 |
Why?
|
Patient Discharge | 1 | 2010 | 3318 | 0.010 |
Why?
|
R Factors | 1 | 1997 | 44 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2002 | 1680 | 0.010 |
Why?
|
Cell Survival | 1 | 2006 | 5882 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1997 | 1681 | 0.010 |
Why?
|
Drug Therapy | 1 | 1997 | 497 | 0.010 |
Why?
|
Macrophages | 1 | 2009 | 5660 | 0.010 |
Why?
|
Cytokines | 1 | 2009 | 7323 | 0.010 |
Why?
|
Cell Division | 1 | 2000 | 4569 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2003 | 5974 | 0.010 |
Why?
|
Apoptosis | 1 | 2007 | 9724 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2004 | 5023 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2001 | 5867 | 0.010 |
Why?
|
Cell Line | 1 | 2003 | 16000 | 0.010 |
Why?
|
DNA Repair | 1 | 1997 | 2046 | 0.000 |
Why?
|